Elevated plasma homocysteine: Cause or consequence of myocardial infarction

Journal of Internal Medicine

Volumn 256, Issue 6, 2004, Pages 491-498

  Hultdin, J ^a   Thoøgersen, Anna Margrethe ^a,b   Jansson, J H ^c   Nilsson, T K ^d   Weinehall, L ^a   Hallmans, G ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

^c UMEÅ UNIVERSITY   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Albumin; Creatinine; Homocysteine; Myocardial infarction; Risk determinants

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; HOMOCYSTEINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; FOLLOW UP; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PLASMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SCREENING TEST; SWEDEN;

CASE-CONTROL STUDIES; CREATININE; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SMOKING;

EID: 9644276933     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01415.x     Document Type: Article

References (43)

1. Wald DS. Law M. Morris JK. Homocysteine and cardiovasculardisease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202-6.
2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
3. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-32.
4. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies, Int J Epidemiol 2002; 31: 59-70.
5. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000; 86: 1005-9.
6. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015-23.
7. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-32.
8. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-75.
9. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med 2000; 160: 422-34.
10. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
11. Thøgersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
12. Huhtasaari F, Asplund K, Wester PO. Cardiovasacular risk factors in the northern Sweden MONICA Study. Acta Med Scand 1988; 224: 99-108.
13. Tunstall-Pedoe H, Kuulasmaa K, Mæhönen M, Tolonen H, Ruokokoski E, Amouyel P, for the WHO Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project. Lancet 1999; 353: 1547-57.
14. Söderberg S, Ahren B, Jansson JH et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999; 246: 409-18.
15. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott Imx® Analyzer. Clin Chem 1995; 41: 991-94.
16. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
17. Lange H, Suryapranata H De Luca G et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350: 2673-81.
18. Graham IM, O'Callaghan P. Symposium: Vitamin therapy and ischemic heart disease. Vitamins, homocysteine and cardiovascular risk. Cardiovasc Drugs Ther 2002; 16: 383-9.
19. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, and the MTHFR Studies Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-31.
20. 677→T mutation of 5.10-methylenetetrahydrofolate reductase and total plasma homocyst(e)ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis 2001; 12: 85-90.
21. Jaques PF, Bostom AG, Wilson PWF, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-21.
22. Verhoef P, Kok FJ, Kruyssen DA et al. Plasma total homocysteine. B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
23. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001; 85: 153-8.
24. Nygård O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
25. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995; 237: 381-8.
26. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996; 77: 759-61.
27. Senaratne MPJ, Griffiths J, Nagendran J. Elevation of plasma homocysteine levels associated with acute myocardial infarction. Clin Invest Med 2000; 23: 220-6.
28. Al-Obaidi MK, Stubbs PJ, Amersey R, Noble MIM. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart 2001; 85: 380-4.
29. Gomes E, Duarte R, Reis RP et al. Homocysteine increase after acute myocardial infarction - can it explain the differences between case-control and cohort studies? Rev Port Cardiol 2002; 21: 575-81.
30. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32: 992-9.
31. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001; 38: 1782-7.
32. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97.
33. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insuffiency with treatment and outcomes after myocardial infection in elderly patients. Ann Intern Med 2002; 137: 555-62.
34. Wright RS, Reeder GS, Herzog CA et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137: 563-70.
35. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP, for the Multiple Risk factor Intervention Trial Research Group. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk factor Intervention Trial. Am J Epidemiol 1991; 134: 1266-77.
36. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen. C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
37. Djoussé L, Rothman KJ, Cupples A, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 2002; 106: 2919-24.
38. Law MR, Morris JK, Wald NJ, Hale AK. Serum albumin and mortality in the BUPA study. Int J Epidemiol 1994; 23: 38-41.
39. Corti MC, Salive ME, Guralnik JM. Serum albumin and physical function as predictors of coronary heart disease mortality and incidence in older persons. J Clin Epidemiol 1996; 49: 519-26.
40. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol 1996; 144: 537-47.
41. Tracy RP, Lemaitre RN, Psaty BM et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
42. Gillum RF. Assessment of serum albumin concentration as a risk factor for stroke and coronary disease in African Americans and whites. J Natl Med Assoc 2000; 92: 3-9.
43. Burke AP, Fonseca V, Kolodgie F, Zieske A, Fink L, Virmani R. Increased serum homocysteine and sudden death resulting from coronary atherosclerosis with fibrous plaques. Arterioscler Thromb Vasc Biol 2002; 22: 1936-41.